TITLE

Recurrent hypersensitivity to Combivir

AUTHOR(S)
Winston, Alan; McLean, Ken
PUB. DATE
March 2002
SOURCE
International Journal of STD & AIDS;Mar2002, Vol. 13 Issue 3, p213
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
The non-nucleoside reverse transcriptase inhibitors (NNRTIs) are commonly used in combination antiretroviral therapy and are associated with hypersensitivity reactions on induction therapy. We report a case of recurrent hypersensitivity associated with Combivir, when there was a delay in determining the cause as the NNRTIs were considered to be the more likely cause.
ACCESSION #
22203456

 

Related Articles

  • Antiretroviral therapy in HIV infection: are we using resources appropriately and cost effectively? Horn, C. K.; Dodds, R.; Scott, G. R. // International Journal of STD & AIDS;Oct1999, Vol. 10 Issue 10, p689 

    The provision of antiretroviral therapy to HIV-positive patients attending the Department of Genitourinary Medicine at the Royal Infirmary of Edinburgh was assessed, to examine whether clinicians were offering treatment in line with the departmental protocol. A total of 195 patients attended in...

  • Adverse drug events due to Antiretroviral Therapy in a Northern Indian Tertiary Care Institution. Sadiq, Shamiya; Gupta, Sapna; Khajuria, Vijay; Tondon, Vishal R.; Mahajan, Annil; Gupta, Mrityunjay // National Journal of Physiology, Pharmacy & Pharmacology;2016, Vol. 6 Issue 3, p205 

    The article offers information on the adverse effects of antiretroviral therapy in a tertiary care hospital in India. Ninety patients who were undergoing antiretroviral therapy were evaluated prospectively over a period of six months and were examined for adverse effects. Most of the adverse...

  • Nelfinavir/nevirapine/zidovudine withdrawal.  // Reactions Weekly;5/1/2004, Issue 999, p12 

    Discuses research being done on the development of multiple organ failure in a woman patient receiving nelfinavir, nevirapine and zidovudine for HIV infection. Reference to a study by M. Crespo et al published in a January 2004 issue of the "European Journal of Clinical Microbiology and...

  • Combination of Antiretroviral Drugs as Microbicides. Balzarini, Jan; Schols, Dominique // Current HIV Research;Jan2012, Vol. 10 Issue 1, p53 

    Tenofovir, a highly prescribed drug for the treatment of HIV/AIDS infections, has recently also shown its effectiveness as a potential topical microbicide drug in the prevention of HIV transmission. Here, we discuss the combination of tenofovir with various other antiretrovirals (ARV)...

  • Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial. Tashima, Karen; Crofoot, Gordon; Tomaka, Frank L.; Kakuda, Thomas N.; Brochot, Anne; van de Casteele, Tom; Opsomer, Magda; Garner, William; Margot, Nicolas; Custodio, Joseph M.; Fordyce, Marshall W.; Szwarcberg, Javier // AIDS Research & Therapy;2014, Vol. 11, p1 

    Background Cobicistat is an alternative pharmacoenhancer to ritonavir. In healthy volunteers, darunavir exposure was comparable when darunavir 800 mg once-daily was co-administered with cobicistat 150 mg once-daily (as single agents or a fixed-dose combination) vs. with ritonavir 100 mg once...

  • Zidovudine/Lamivudine for HIV-1 Infection Contributes to Limb Fat Loss. van Vonderen, Marit G. A.; van Agtmael, Michiel A.; Hassink, Elly A. M.; Milinkovic, Ana; Brinkman, Kees; Geerlings, Suzanne E.; Ristola, Matti; van Eeden, Arne; Danner, Sven A.; Reiss, Peter // PLoS ONE;2009, Vol. 4 Issue 5, p1 

    Background: Lipoatrophy is known to be associated with stavudine as part of the treatment for HIV infection, but it is less clear if this serious side effect is also related to other nucleoside reverse transcriptase inhibitors like zidovudine. We aimed to determine whether zidovudine-sparing...

  • Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda. Goodall, R. L.; Dunn, D. T.; Pattery, T.; van Cauwenberge, A.; Nkurunziza, P.; Awio, P.; Ndembi, N.; Munderi, P.; Kityo, C.; Gilks, C. F.; Kaleebu, P.; Pillay, D. // Journal of Antimicrobial Chemotherapy (JAC);Jul2014, Vol. 69 Issue 7, p1938 

    Objectives We investigated phenotypic and genotypic resistance after 2 years of first-line therapy with two HIV treatment regimens in the absence of virological monitoring. Methods NORA [Nevirapine OR Abacavir study, a sub-study of the Development of AntiRetroviral Therapy in Africa (DART)...

  • Severe skin rash with lamivudine in HIV infected patients:Some unusual case reports. Modak, Dolanchampa; Guha, Subhasish Kamal // Indian Journal of Pharmacology;May/Jun2013, Vol. 45 Issue 3, p298 

    Lamivudine (3TC) is a nucleoside reverse transcriptase inhibitor (NRTI) licensed for as a first line drug in Human immunodeficiency virus (HIV) infection and also in the treatment of hepatitis B. It is relatively nontoxic in nature and potentiates the antiviral effects of other NRTIs like...

  • Antiretroviral Pre-Exposure Prophylaxis Does Not Enhance Immune Responses to HIV in Exposed but Uninfected Persons. Pattacini, Laura; Murnane, Pamela M.; Baeten, Jared M.; Fluharty, Tayler R.; Thomas, Katherine K.; Bukusi, Elizabeth; Katabira, Elly; Mugo, Nelly; Donnell, Deborah; Lingappa, Jairam R.; Celum, Connie; Marzinke, Mark; McElrath, M. Juliana; Lund, Jennifer M. // Journal of Infectious Diseases;6/15/2015, Vol. 211 Issue 12, p1943 

    Background. Antiretroviral preexposure prophylaxis (PrEP), using daily oral combination tenofovir disoproxil fumarate plus emtricitabine, is an effective human immunodeficiency virus (HIV) prevention strategy for populations at high risk of HIV acquisition. Although the primary mode of action...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics